Literature DB >> 34986240

Cost-Benefit Analysis of Novel Antiviral Ritonavir in the Active Duty U.S. Military Population.

Daphne Morrison Ponce1, Levi K Kitchen1, John J Devlin2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34986240     DOI: 10.1093/milmed/usab552

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.563


× No keyword cloud information.
  1 in total

Review 1.  First-generation oral antivirals against SARS-CoV-2.

Authors:  Parham Sendi; Raymund R Razonable; Sandra B Nelson; Alex Soriano; Rajesh Tim Gandhi
Journal:  Clin Microbiol Infect       Date:  2022-05-08       Impact factor: 13.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.